ProQR Therapeutics N.V.
PRQR Healthcare Biotechnology
ProQR Therapeutics N.V.’s revenue for fiscal 2025 (year ended December 2025) was $18.0 million, down 12.0% from fiscal 2024. In the quarter to June 2026, revenue grew 135.0%, EPS grew 28.6%, free cash flow fell 1.06% and total debt rose 8.71%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow PRQR
ProQR Therapeutics N.V. (PRQR) EV/Sales
As of 16 October 2026, ProQR Therapeutics N.V. (PRQR) trades at a EV/Sales of 0.9×. Over the past ten years it has ranged from −32.8× (May 2022) to 45.6× (December 2022); the current reading is higher than 73% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 6.6× | 76.92% |
| FY2024 | 3.7× | (44.22%) |
| FY2023 | 6.7× | (81.30%) |
| FY2022 | 35.6× | — |
| FY2021 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 3.7× | (33.50%) |
| Mar 2026 | 5.5× | (16.06%) |
| Dec 2025 | 6.6× | 2.37% |
| Sep 2025 | 6.4× | 29.52% |
| 17 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| IFRX InflaRx N.V. compare | −1,061× |
| LYEL Lyell Immunopharma, Inc. compare | −550× |
| ZNTL Zentalis Pharmaceuticals, Inc. compare | n/m |
| LRMR Larimar Therapeutics, Inc. compare | n/m |
| IVVD Invivyd, Inc. compare | 0.7× |
| CGEN Compugen Ltd. compare | 0.8× |
| PRQR ProQR Therapeutics N.V. | 0.9× |
| NAGE Niagen Bioscience, Inc. compare | 1.0× |
| RNAC Cartesian Therapeutics, Inc. compare | 56.5× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)